Curcumin Derivative J-147 Treat AD,Anti-aging,Depressive Disorder(MDD)

www.aasraw.com

Curcumin Derivative J-147 Treat AD,Anti-aging,Depressive Disorder(MDD)

Curcumin Derivative J-147 TreatAD,Anti-aging,Depressive Disorder(MDD)............................................ 1 J-147 Reviews.............................................................................................................................. 2 Learn more about J-147 Work(Mechanism)................................................................................... 3 Quick View Benefits of J-147..........................................................................................................3 J-147Treat Alzheimer’s Disease(AD).............................................................................................4 J-147 andAD: Background ...................................................................................................4 J 147 andAD: Experimental derivation analysis on Mice......................................................... 5 Conclusion on J-147 forAD................................................................................................... 6 J-147TreatAging Problem.............................................................................................................6 J-147 and Anti-aging: Background ........................................................................................ 6 J-147 andAnti-aging: Experimental derivation analysis on Mice.............................................. 7 Conclusion on J-147 for aging problem.................................................................................. 8 J-147Treat Major depressive disorder(MDD)................................................................................. 8 J-147 and MDD: Background................................................................................................ 8 J-147 and MDD: Experimental derivation analysis on Mice..................................................... 9 Conclusion on J-147 for Major depressive disorder(MDD).................................................... 10 More ResearchAbout J-147........................................................................................................ 10 WhereTo Buy J-147 Powder?..................................................................................................... 10 Reference........................................................................................................................... 11

1

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

J-147 Reviews Curcumin is a polyphenol and the active component of Turmeric and Ginger.Curcumin has many proven benefits in treating numerous diseases, but due to its poor ability to cross the Blood-Brain Barrier (BB), there are clear limitations.

Basically, J147(CAS:1146963-51-0) is a Curcumin and Cyclohexyl-Bisphenol A (CBA) derivative that is a potent neurogenic and neuroprotective drug. It was developed for the use of treating neurodegenerative conditions associated with aging. J147 can cross the BBB into the brain (strong) and induce neuronal stem cell production.

Unlike the current drugs approved for Alzheimer’s Disease, J147 is neither an acetylcholinesterase inhibitor nor a phosphodiesterase inhibitor, yet it enhances cognition with a short-term treatment.

In this post, we will discuss how the curcumin derivative J147 treat Alzheimer’s Disease(AD), major depressive disorder(MDD) and Anti-aging.

Here is the contents:

1.

2.

3.

4.

5.

6.

7.

Learn more about J-147 Work(Mechanism) Quick View Benefits of J-147 J-147 Treat Alzheimer’s Disease(AD) J-147 Treat Aging Problem J-147 Treat Major depressive disorder(MDD) More Research About J-147 Where To Buy J-147 Powder

2

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

Learn more about J-147 Work(Mechanism) Until 2018, the J-147 effect on the cell remained mysterious until the Salk Institute Neurobiologists decoded the puzzle. The drug works by binding to ATP synthase. This mitochondrial protein modulates the production of cellular energy, hence, controlling the aging process.The presence of the J-147 supplement in the human system prevents age-related toxicities that result from dysfunctional mitochondria and overproduction of ATP. J-147 mechanism of action will also augment the levels of various neurotransmitters including NGF and BDNF. Besides, it acts on the beta-amyloid levels, which are always high among patients with Alzheimer’s and dementia. J-147 effects include slowing the progression of Alzheimer’s, preventing memory deficit, and augmenting the production of neuronal cells.

AASraw is the professional manufacturer of Curcumin Derivative J-147.

Quick View Benefits of J-147 3

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

❶ Improves Mitochondrial Function And Longevity ❷ Prevents Alzheimer’s Disease ❸ Improves Memory ❹ Grows The Brain ❺ Protects Neurons ❻ May Improve Diabetes ❼ Fights Pain And Neuropathy ❽ May Improve Anxiety

J-147 Treat Alzheimer’s Disease(AD) J-147 and AD: Background Currently, the major drug discovery paradigm for neurodegenerative diseases is based upon high affinity ligands for single disease-specific targets. For Alzheimer’s disease (AD), the focus is the amyloid beta peptide (Ass) that mediates familial Alzheimer’s disease pathology. However, given that age is the greatest risk factor for AD, we explored an alternative drug discovery scheme that is based upon efficacy in multiple cell culture models of age-associated pathologies rather than exclusively amyloid metabolism. Using this approach, we identified an exceptionally potent, orally active, neurotrophic molecule that facilitates memory in normal rodents, and prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model.

4

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

J 147 and AD: Experimental derivation analysis on Mice INTRODUCTION: Despite years of research, there are no disease-modifying drugs for Alzheimer’s disease (AD), a fatal, age-related neurodegenerative disorder. Screening for potential therapeutics in rodent models of AD has generally relied on testing compounds before pathology is present, thereby modeling disease prevention rather than disease modification. Furthermore, this approach to screening does not reflect the clinical presentation of AD patients which could explain the failure to translate compounds identified as beneficial in animal models to disease modifying compounds in clinical trials.

Clearly a better approach to pre-clinical drug screening for AD is required.

METHODS: To more accurately reflect the clinical setting, we used an alternative screening strategy involving the treatment of AD mice at a stage in the disease when pathology is already advanced. Aged (20-month-old) transgenic AD mice (APP/swePS1DeltaE9) were fed an exceptionally potent, orally active, memory enhancing and neurotrophic molecule called J147. Cognitive behavioral assays, histology, ELISA and Western blotting were used to assay the effect of J147 on memory, amyloid metabolism and neuroprotective pathways. J147 was also investigated in a scopolamine-induced model of memory impairment in C57Bl/6J mice and compared to donepezil. Details on the pharmacology and safety of J147 are also included.

5

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

RESULTS: Data presented here demonstrate that J147 has the ability to rescue cognitive deficits when administered at a late stage in the disease. The ability of J147 to improve memory in aged AD mice is correlated with its induction of the neurotrophic factors NGF (nerve growth factor) and BDNF (brain derived neurotrophic factor) as well as several BDNF-responsive proteins which are important for learning and memory. The comparison between J147 and donepezil in the scopolamine model showed that while both compounds were comparable at rescuing short term memory, J147 was superior at rescuing spatial memory and a combination of the two worked best for contextual and cued memory.

Conclusion on J-147 for AD J147 is an exciting new compound that is extremely potent, safe in animal studies and orally active. J147 is a potential AD therapeutic due to its ability to provide immediate cognition benefits, and it also has the potential to halt and perhaps reverse disease progression in symptomatic animals as demonstrated in these studies.

J-147 Treat Aging Problem J-147 and Anti-aging: Background Mice treated with J147 had better memory and cognition, healthier blood vessels in the brain and other improved physiological features…

“Initially, the impetus was to test this drug in a novel animal model that was more similar to 99%of Alzheimer’s cases,” says Antonio Currais, a member of Professor David Schubert’s Cellular Neurobiology Laboratory at Salk. “We did not predict we’d see this sort of anti-aging effect, but J147 made old mice look like they were young, based upon a number of physiological parameters.” “While most drugs developed in the past 20 years target the amyloid plaque deposits in the brain (which are a hallmark of the disease), none have proven effective in the clinic,” says Schubert.

Several years ago, Schubert and his colleagues began to approach the treatment of the disease from a new angle. Rather than target amyloid, the lab decided to zero in on the major risk factor for the disease – old age. Using cell-based screens against old age-associated brain toxicities, they synthesized J147.

Previously, the team found that J147 could prevent and even reverse memory loss and Alzheimer’s pathology in mice that have a version of the inherited form of Alzheimer’s, the 6

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

most commonly used mouse model. However, this form of the disease comprises only about 1% of Alzheimer’s cases. For everyone else, old age is the primary risk factor, says Schubert. The team wanted to explore the effects of the drug candidate on a breed of mice that age rapidly and experience a version of dementia that more closely resembles the age-related human disorder.

J-147 and Anti-aging: Experimental derivation analysis on Mice In this latest work, the researchers used a comprehensive set of assays to measure the expression of all genes in the brain, as well as over 500 small molecules involved with metabolism in the brains and blood of three groups of the rapidly aging mice. The three groups of rapidly aging mice included one set that was young, one set that was old and one set that was old but fed J147 as they aged.

The old mice that received J147 performed better on memory and other tests for cognition and also displayed more robust motor movements. The mice treated with J147 also had fewer pathological signs of Alzheimer’s in their brains. Importantly, because of the large amount of data collected on the three groups of mice, it was possible to demonstrate that many aspects of gene expression and metabolism in the old mice fed J147 were very similar to those of the young animals. These included markers for increased energy metabolism, reduced brain inflammation and reduced levels of oxidized fatty acids in the brain.

7

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

Another notable effect was that J147 prevented the leakage of blood from the microvessels in the brains of old mice. “Damaged blood vessels are a common feature of aging in general, and in Alzheimer’s, it is frequently much worse,” says Currais.

AASraw is the professional manufacturer of Curcumin Derivative J-147.

Conclusion on J-147 for aging problem Mice fed J147 had increased energy metabolism and reduced brain inflammation.Researchers have found that an experimental drug candidate aimed at combating Alzheimer’s disease, called J147, has a host of unexpected anti-aging effects in animals.

The team from the Salk Institute showed that the drug candidate worked well in a mouse model of aging not typically used in Alzheimer’s research. When these mice were treated with J147, they had better memory and cognition, healthier blood vessels in the brain and other improved physiological features.

J-147 Treat Major depressive disorder(MDD) J-147 and MDD: Background Major depressive disorder (MDD) is a severe mental disorder related to the deficiency of monoamine neurotransmitters, particularly to abnormalities of 5-HT (5-hydroxytryptamine, serotonin) and its receptors. Our previous study suggested that acute treatment with a novel curcumin derivative J147 exhibited antidepressant-like effects by increasing brain derived neurotrophic factor (BDNF) level in the hippocampus of mice. The present study expanded upon our previous findings and investigated the antidepressant-like effects of sub-acute treatment of J147 for 3 days in male ICR mice and its possible relevancy to 5-HT1A and 5-HT1B receptors and downstream cAMP-BDNF signaling.

8

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

J-147 and MDD: Experimental derivation analysis on Mice Methods: J147 at doses of 1, 3, and 9 mg/kg (via gavage) was administered for 3 days, and the anti-immobility time in the forced swimming and tail suspension tests (FST and TST) was recorded. The radioligand binding assay was used to determine the affinity of J147 to 5-HT1A and 5-HT1B receptor. Moreover, 5-HT1A or 5-HT1B agonist or its antagonist was used to determine which 5-HT receptor subtype is involved in the antidepressant-like effects of J147. The downstream signaling molecules such as cAMP, PKA, pCREB, and BDNF were also measured to determine the mechanism of action.

Results: The results demonstrated that sub-acute treatment of J147 remarkably decreased the immobility time in both the FST and TST in a dose-dependent manner.

J147 displayed high affinity in vitro to 5-HT1A receptor prepared from mice cortical tissue and was less potent at 5-HT1B receptor. These effects of J147 were blocked by pretreatment with a 5-HT1A antagonist NAD-299 and enhanced by a 5-HT1A agonist 8-OH-DPAT. However, 5-HT1B receptor antagonist NAS-181 did not appreciably alter the effects of J147 on depression-like behaviors. Moreover, pretreatment with NAD-299 blocked J147-induced increases in cAMP, PKA, pCREB, and BDNF expression in the hippocampus, while 8-OH-DPAT enhanced the effects of J147 on these proteins’ expression.

9

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

Conclusion on J-147 for Major depressive disorder(MDD) The results suggest that J147 induces rapid antidepressant-like effects during a 3-day treatment period without inducing drug tolerance. These effects might be mediated by 5-HT1A-dependent cAMP/PKA/pCREB/BDNF signaling.

More Research About J-147 ※ T-006: How To Make This Improved Alternative To J-147 ※ J147 is a phenyl hydrazide derived from the natural compound curcumin. ※ J147 has a half-life of 2.5 hrs in the brain, 1.5 hrs in plasma, 4.5min in human microsomes, and <4min in mouse microsomes. ※Chronic oral treatment with J147 protected the sciatic nerve from progressive diabetes-induced slowing of large myelinated fiber conduction velocity while single doses of J147 rapidly and transiently reversed established touch-evoked allodynia. ※ J147 treatment down-regulated BACE, thus increasing APP (improper APP cleavage eventually gives rise to Aβ). ※ The mitochondrial α-F1 subunit of ATP synthase (ATP5A) as a high affinity molecular target of J147, a protein previously studied in the context of aging…has dose dependent inhibition on ATP5a. ※ J147 restored the levels of acylcarnitines suggesting a positive effect on mitochondrial dynamics. ※ In NMDA receptors, T-006 inhibits excessive Ca2+ influx. ※ T-006 has a protective role in this system through both inhibiting MAPK/ERK pathway and restoring PI3-K/Akt pathway. ※Other derivatives such as 3j (dicyanovinyl-substituted J147 analogue) can inhibit oligomerization and fibrillation of β-amyloid peptides and protects neuronal cells from β-amyloid-induced cytotoxicity.

Where To Buy J-147 Powder?

10

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

The legality of this nootropic is still a bone of contention but it will not bar you from acquiring legitimate products. After all, J-147 Alzheimer’s clinical trials are underway. You can purchase the powder in online stores as you get the privilege to compare J-147 prices across different sellers. However, you should make sure to shop around from valid suppliers with independent laboratory testing.

If you want some J-147 for sale, check in with our store. We supply numerous nootropics under quality control. You can buy in bulk or make single purchases depending on your psychonautic goal. Note that, J-147 price is friendly only when you buy in large quantities.

AASraw is the professional manufacturer of Curcumin Derivative J-147.

Reference [1] Prior M, et al. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimers Res Ther. 2013 May 14;5(3):25.

[2] Chen Q, et al. A novel neurotrophic drug for cognitive enhancement and Alzheimer’s disease. PLoS One. 2011;6(12):e27865.

[3] Currais A, Goldberg J, Farrokhi C, Chang M, Prior M, Dargusch R, Daugherty D, Armando A, Quehenberger O, Maher P, Schubert D: A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging (Albany NY). 2015 Nov;7(11):937-55. doi: 10.18632/aging.100838. [PubMed:26564964] [4] Daugherty DJ, Marquez A, Calcutt NA, Schubert D: A novel curcumin derivative for the treatment of diabetic neuropathy. Neuropharmacology. 2018 Feb;129:26-35. doi: 10.1016/j.neuropharm.2017.11.007. Epub 2017 Nov 6. [PubMed:29122628] [5] J. Goldberg, A. Currais, M. Prior, W. Fischer, C. Chiruta, E. Ratliff, D. Daugherty, R. Dargusch, K. Finley, P.B. Esparza-Molto, J.M. Cuezva, P. Maher, M. Petrascheck, D. Schubert [6] Solomon B (October 2008). “Filamentous bacteriophage as a novel therapeutic tool for Alzheimer’s disease treatment”. Journal of Alzheimer’s Disease. 15 (2): 193–8. PMID 18953108.

[7] Wang M, et al. The first synthesis of [11C]J147, a new potential PET agent for imaging of Alzheimer’s disease. Bioorg Med Chem Lett. 2013 Jan 15;23(2):524-7.

[8] Prior M, et al. Selecting for neurogenic potential as an alternative for Alzheimer’s disease drug discovery. Alzheimers Dement. 2016 Jun;12(6):678-86.

11

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com